Search

Your search keyword '"European Project: 246479,EC:FP7:NMP,FP7-NMP-2009-LARGE-3,NAMDIATREAM(2010)"' showing total 3 results
Start Over Author "European Project: 246479,EC:FP7:NMP,FP7-NMP-2009-LARGE-3,NAMDIATREAM(2010)"
3 results on '"European Project: 246479,EC:FP7:NMP,FP7-NMP-2009-LARGE-3,NAMDIATREAM(2010)"'

1. Engineering of ultra-small diagnostic nanoprobes through oriented conjugation of single-domain antibodies and quantum dots

Author

Igor Nabiev, Alyona Sukhanova, Klervi Even-Desrumeaux, Patrick Chames, Daniel Baty, Mikhail Artemyev, Vladimir Oleinikov, Laboratoire de Recherche en Nanosciences - EA 4682 (LRN), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-SFR Condorcet, Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Belarusian State University, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (IBCh RAS), Russian Academy of Sciences [Moscow] (RAS), European Project: 246479,EC:FP7:NMP,FP7-NMP-2009-LARGE-3,NAMDIATREAM(2010), SFR Condorcet, Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-SFR Condorcet, Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS), Nabiev, Igor, and NANOTECHNOLOGICAL TOOLKITS FOR MULTI-MODAL DISEASE DIAGNOSTICS AND TREATMENT MONITORING - NAMDIATREAM - - EC:FP7:NMP2010-07-01 - 2014-06-30 - 246479 - VALID

Subjects
medicine.drug_class, [SPI.NANO] Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, Nanoparticle, Nanotechnology, quantum dots, 02 engineering and technology, Conjugated system, 010402 general chemistry, Monoclonal antibody, 01 natural sciences, Flow cytometry, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, medicine, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, General Environmental Science, Plasmonic nanoparticles, diagnostic nanoprobes, Bioconjugation, medicine.diagnostic_test, cancer diagnostics, Chemistry, flow cytometry, single-domain antibodies, imaging, 021001 nanoscience & nanotechnology, 0104 chemical sciences, Quantum dot, immunohistochemistry, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], General Earth and Planetary Sciences, 0210 nano-technology, oriented conjugation, Conjugate
Abstract

International audience; Nanoparticle-based biodetection commonly employs monoclonal antibodies (mAbs) for targeting. Although several types of conjugates have been used for biomarker labeling, the large size of mAbs limits the number of ligands per nanoparticle, impedes their intratumoral distribution, and limits intracellular penetration. Furthermore, the conditions of mAb conjugation using conventional techniques provide nanoprobes with irregular orientation of mAbs on the nanoparticle surface and often provoke mAb unfolding. Here, we have developed a protocol to engineer ultrasmall diagnostic nanoprobes through directional conjugation of semiconductor quantum dots (QDs) with 13-kDa single-domain antibodies (sdAbs) derived from llama immunoglobulin G (IgG). sdAbs are conjugated with QDs in a highly oriented manner via an additional cysteine residue specifically integrated into the sdAb C-terminus. The resultant nanoprobes are

Published
2021

2. Nonlinear optical and magnetic properties of BiFeO3 harmonic nanoparticles

Author

Luigi Bonacina, Solène Passemard, Davide Staedler, Adriele Prina-Mello, Laurent Badie, Yannick Mugnier, Ronan Le Dantec, Jean-Pierre Wolf, Christine Galez, Andrii Rogov, Daniel Rytz, Céline Joulaud, Gareth Clarke, Yuri Volkov, Thomas Jüstel, Thibaud Magouroux, Sebastian Schwung, Sandrine Gerber-Lemaire, Laboratoire SYstèmes et Matériaux pour la MEcatronique (SYMME), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), and European Project: 246479,EC:FP7:NMP,FP7-NMP-2009-LARGE-3,NAMDIATREAM(2010)

Subjects
[PHYS.PHYS.PHYS-OPTICS]Physics [physics]/Physics [physics]/Optics [physics.optics], Materials science, [PHYS.PHYS]Physics [physics]/Physics [physics], Analytical chemistry, General Physics and Astronomy, Nanoparticle, Nonlinear optics, Second-harmonic generation, ddc:500.2, Magnetic hysteresis, Molecular physics, symbols.namesake, Microscopy, Harmonic, symbols, [PHYS.COND.CM-MS]Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci], Particle, Rayleigh scattering, ComputingMilieux_MISCELLANEOUS
Abstract

Second Harmonic Generation (SHG) from BiFeO3 nanocrystals is investigated for the first time to determine their potential as biomarkers for multiphoton imaging. Nanocrystals are produced by an auto-combustion method with 2-amino-2-hydroxymethyl-propane-1,3-diol as a fuel. Stable colloidal suspensions with mean particle diameters in the range 100–120 nm are then obtained after wet-milling and sonication steps. SHG properties are determined using two complementary experimental techniques, Hyper Rayleigh Scattering and nonlinear polarization microscopy. BiFeO3 shows a very high second harmonic efficiency with an averaged hdi coefficient of 79612 pm/V. From the nonlinear polarization response of individual nanocrystals, relative values of the independent dij coefficients are also determined and compared with recent theoretical and experimental studies. Additionally, the particles show a moderate magnetic response, which is attributed to gamma-Fe2O3 impurities. A combination of high nonlinear optical efficiency and magnetic response within the same particle is of great interest for future bio-imaging and diagnostic applications.

Published
2014

3. A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy

Author

Daniel Baty, Brigitte Kerfelec, Patrick Chames, Pierre Bruhns, Marc Turini, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by INSERM, CNRS and INSERM-Transfert (Procop). Marc Turini received funding from the European Commission through the FP7 Cooperation Program, grant no. NMP-2009-4.0-3-246479 NAMDIATREAM FP7, We are greatly indebted to Rémy Castellano, Yves Collette, Armelle Goubard and Laurent Pouyet of the TrGET preclinical assay platform (U1068 INSERM, Marseille, France) for their precious technical assistance with xenografted models. We also thank Dr Picard (EFS, Marseille) for providing NK cells of different FcγRIIIA-158 polymorphism, the cell culture platform and the mice facilities of Marseille-Luminy (France), European Project: 246479,EC:FP7:NMP,FP7-NMP-2009-LARGE-3,NAMDIATREAM(2010), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Kerfelec, Brigitte, and NANOTECHNOLOGICAL TOOLKITS FOR MULTI-MODAL DISEASE DIAGNOSTICS AND TREATMENT MONITORING - NAMDIATREAM - - EC:FP7:NMP2010-07-01 - 2014-06-30 - 246479 - VALID

Subjects
FcγRIIIA polymorphism, Receptor, ErbB-2, medicine.medical_treatment, Cell, Mice, Nude, Antineoplastic Agents, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Antibodies, Monoclonal, Humanized, Jurkat cells, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, Jurkat Cells, Mice, Random Allocation, Breast cancer, breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Trastuzumab, In vivo, Cell Line, Tumor, HER2, Antibodies, Bispecific, medicine, Animals, Humans, skin and connective tissue diseases, [SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunity, Antibody-dependent cell-mediated cytotoxicity, Receptors, IgG, Immunotherapy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.disease, Xenograft Model Antitumor Assays, 3. Good health, Killer Cells, Natural, trastuzumab, bispecific antibody, medicine.anatomical_structure, Oncology, Mechanism of action, Immunology, Female, medicine.symptom, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.drug, Research Paper
Abstract

International audience; Trastuzumab is established as treatment of HER2high metastatic breast cancers but many limitations impair its efficacy. Here, we report the design of a Fab-like bispecific antibody (HER2bsFab) that displays a moderate affinity for HER2 and a unique, specific and high affinity for FcγRIII. In vitro characterization showed that ADCC was the major mechanism of action of HER2bsFab as no significant HER2-driven effect was observed. HER2bsFab mediated ADCC at picomolar concentration against HER2high, HER2low as well as trastuzumab-refractive cell lines. In vivo HER2bsFab potently inhibited HER2high tumor growth by recruitment of mouse FcγRIII and IV-positive resident effector cells and more importantly, exhibited a net superiority over trastuzumab at inhibiting HER2low tumor growth. Moreover, FcγRIIIA-engagement by HER2bsFab was independent of V/F158 polymorphism and induced a stronger NK cells activation in response to target cell recognition. Thus, taking advantage of its epitope specificity and affinity for HER2 and FcγRIIIA, HER2bsFab exhibits potent anti-tumor activity against HER2low tumors while evading most of trastuzumab Fc-linked limitations thereby potentially enlarging the number of patients eligible for breast cancer immunotherapy.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results